L-asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia

Applied Biochemistry and Biotechnology

Volumn 167, Issue 8, 2012, Pages 2144-2159

  Ramya, L N ^a   Doble, Mukesh ^b   Rekha, V P B ^c   Pulicherla, K K ^c  

^a ACHARYA NAGARJUNA UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^c RVR JC COLLEGE OF ENGINEERING   (India)

Author keywords

Acute lymphoblastic leukaemia; Dual substrate specificity; Glutaminase side activity; L Asparaginase; Pectobacterium carotovorum

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKAEMIA; GLUTAMINASE; L-ASPARAGINASE; PECTOBACTERIUM CAROTOVORUM; SUBSTRATE SPECIFICITY;

BOTTLES; CHEMOTHERAPY;

ENZYME ACTIVITY;

ANTHRACYCLINE DERIVATIVE; ANTITHROMBIN III; ASPARAGINASE; ASPARAGINASE MACROGOL; CHOLESTEROL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; GLUTAMINASE; INSULIN; LIPID; MACROGOL; MERCAPTOPURINE; METHOTREXATE; PLASMINOGEN; PREDNISONE; PROTEIN C; PROTEIN S; STEROID; TRIACYLGLYCEROL; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LIVER FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PANCREATITIS; AGITATION; AMINO ACID SUBSTITUTION; ANAPHYLAXIS; ANOREXIA; BACKACHE; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; COMA; CONJUNCTIVAL HYPEREMIA; CONVULSION; CORNEA DISEASE; DIABETES MELLITUS; DISORIENTATION; DRUG CONTAMINATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; EYE PAIN; FOREIGN BODY REACTION; GROWTH HORMONE DEFICIENCY; HALLUCINATION; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERVISCOSITY SYNDROME; HYPOLIPEMIA; IMMUNE DEFICIENCY; INSULIN BLOOD LEVEL; LETHARGY; LEUKEMIA; LEUKEMIC MENINGITIS; LEUKOPENIA; LIPID METABOLISM; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREATITIS; PAROTITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECOND CANCER; SEIZURE; SIDE EFFECT; SITE DIRECTED MUTAGENESIS; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS; VOMITING;

ANIMALS; ASPARAGINASE; GLUTAMINASE; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANIMALIA; BACTERIA (MICROORGANISMS); PECTOBACTERIUM CAROTOVORUM;

EID: 84866345798     PISSN: 02732289     EISSN: 15590291     Source Type: Journal    
DOI: 10.1007/s12010-012-9755-z     Document Type: Review

References (174)

1. Jacobs, A. D., & Gale, R. P. (1984). Recent advances in the biology and treatment of acute lymphoblastic leukaemia in adults. The New England Journal of Medicine, 311, 1219.
2. Pinkel, D. (1987). Curing children of leukaemia. Cancer, 60(1), 683.
3. Ries, L. A., Smith, M. A., Gurney, J. G., Linet, M., Tamra, T., Young, J. L., Bunin, G. R. (eds) (1999). Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute. 13, 335-342.
4. Pui, C.H., Sandlund, J. T., Pei, D., Campana, D., Rivera,G. K., Ribeiro, R. C., Rubnitz, J. E., Razzouk, B. I., Howard, S. C., Hudson, M. M., Cheng, C., Kun, L. E., Raimondi, S. C., Behm, F. G., Downing, J. R., Relling, M. V., & William, E. (2004). Improved outcome for children with acute lymphoblastic leukaemia: Results of total therapy study XIIIB at St Jude Children's Research Hospital. Blood, 104, 2690-2696.
5. Silverman, L. B., Gelber, R. D., Dalton, V. K., Assenlin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moqhrabi, A., Samson Assenlin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moqhrabi, A., Samson, Y., Schorin, M. A., Arkin, S., Declerck, L., Cohen, H. J., & Sallan, S. E. (2001). Improved outcome for children with acute lymphoblastic leukaemia: Results of Dana-Farber consortium protocol 91-01. Blood, 97, 1211-1218.
6. Burger, B., Zimmermann, M., Mann, G., Kuhl, J., Loning, L., Riehm, H., Reiter, A., & Schrappe, M. (2003). Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukaemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture. Journal of Clinical Oncology, 21, 179-181.
7. Smith, M., Arthur, D., Camitta, B., Carroll, A. J., Crist, W., Gaynon, P., Gelber, R., Heerema, N., Korn, E. L., Link, M., Murphy, S., Puj, C. H., Pullen, J., Reamon, G., Sallan, S. E., Sather, H., Shuster, J., Simon, R., Trigg, M., Tubergen, D., Uckun, F., & Ungerleider, R. (1996). Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukaemia. Journal of Clinical Oncology, 14, 18-24 [see comments].
8. Weiss, M. A., & Lamanna, N. (2006). In adult ALL, less is now more. Blood, 107, 852-853.
9. Groves, F. D., Linet, M. S., & Devesa, S. S. (1996). Epidemiology of leukaemia: Overview of patterns of occurrence. In E. S. Henderson, T. A. Lister, & M. F. Greaves (Eds.), Leukaemia (6th ed., pp. 145-159). Philadelphia: Saunders.
10. Mastrangelo, R., Poplack, D., Bleyer, A., Riccardi, R., Sather, H., & D'Angio, G. (1986). Report and recommendations of the Rome Workshop Concerning Poor-Prognosis Acute Lymphoblastic Leukaemia in Children: Biologic bases for staging, stratification, and treatment. Medical and Pediatric Oncology, 14, 191-194.
11. Niemeyer, C. M., Hitchcock-Bryan, S., & Sallen, S. E. (1985). Comparative analysis of treatment programs for childhood acute lymphoblastic leukaemia. Seminars in Oncology, 12, 122.
12. Mauer, A. M. (1986). New directions in the treatment of acute lymphoblastic leukaemia in children. The New England Journal of Medicine, 315, 316.
13. Hammond, D., Sather, H., Nesbit, M., Miller, D., Coccia, P., Bleyer, A., Lukens, J., & Siegel, S. (1986). Analysis of prognostic factors in acute lymphoblastic leukaemia. Medical and Pediatric Oncology, 14, 124.
14. Rivera, O. K., & Mauer, A. M. (1987). Controversies in the management of childhood acute lymphoblastic leukaemia: Treatment intensification, CNS leukaemia and prognostic factors. Seminars in Hematology, 24, 12.
15. Riehm, H., Feickert, H. I., Schrappe, M., Henze, G., & Schelbong. (1987). From the BFM Study Group: Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transfus, 30, 139-146.
16. Hoebzer, D., & Gale, R. P. (1987). Acute lymphoblastic leukaemia in adults: Recent progress, future directions. Seminars in Hematology, 24, 27.
17. Hjalgrim, L. L., Westergaard, T., Rostgaard, K., Melbyei, M., Hjalgrim, H., Engels, E. A., et al. (2003). Birth weight as a risk factor for childhood leukaemia: A meta-analysis of 18 epidemiologic studies. American Journal of Epidemiology, 158, 724-735.
18. Ahlbom, A., Day, N., & Feychting, M. (2000). A pooled analysis of magnetic fields and childhood leukaemia. British Journal of Cancer, 83, 692-698.
19. Buer, P. A., Kwan, M. L., Reynolds, P., & Urayama, K. Y. (2005). Environmental and genetic risk factors for childhood leukaemia: Appraising the evidence. Cancer Investigation, 23, 60-75.
20. Li, F. P. (1993). Epidemiology of cancer in childhood. In D. G. Nathan & F. A. Oski (Eds.), Hematology of infancy and childhood (4th ed., p. 1102). Philadelphia: Saunders.
21. Mukhin, V. N. (2000). Acute leukaemia in adults: Morbidity in Donetsk region of Ukraine before and after Chernobyl's accident. Terapevticheski Arkhiv, 72, 60-62.
22. Brown, W. M., & Doll, R. (1965). Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. British Medical Journal, 5474, 1327-1332.
23. Greaves, M. F., & Alexander, F. E. (1993). An infectious etiology for common acute lymphoblastic leukaemia in childhood? Leukaemia, 7, 349-360.
24. Lombardi, L., Newcomb, E. W., & Dalla-Favera, R. (1987). Pathogenesis of Burkett's lymphoma: Expression of an activated c-myc oncogene causes the tumorogenic conversion of EBV-infected B lymphoblasts. Cell, 49, 161-170.
25. Meltzer, A. A., Spitz, M. R., Johnson, C. C., & Culbert, S. J. (1989). Season-of birth and acute leukaemia of infancy. Chronobiology International, 6, 285-289.
26. Timonen, T. T. (1999). A hypothesis concerning deficiency of sunlight, cold temperature, and influenza epidemics associated with the onset of acute lymphoblastic leukaemia in northern Finland. Annals of Hematology, 78, 408-414.
27. Clementi, A. (1922). Desamidation enzymatique de l'L-Asparagine. Archives Internationales de Physiologie, 19, 369.
28. Broome, J. D. (1961). Evidence that the L-Asparaginase activity of guinea pig serum is responsible for its anti-lymphoma effects. Nature, 191, 1114-1115.
29. Broome, J. D. (1963). Evidence that the L-Asparaginase of guinea pig serum is responsible for its antilymphoma effects. I and II. The Journal of Experimental Medicine, 118, 99.
30. Kidd, J. G. (1953). Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum: I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum or rabbit serum. The Journal of Experimental Medicine, 98, 565-582.
31. Winston, J. J., & Yellin, T. (1973). L-Asparaginase: A review. Advances in Enzymology, 39, 185-248.
32. Oettgen, H. F., Old, L. J., & Boyse, E. A. (1967). Inhibition of leukaemias in man by L-asparaginase. Cancer Research, 27, 2619-2631.
33. Hill, J. M., Roberts, J., Loeb, E., MacLellan, H. A., & Hill, R. W. (1967). L-Asparaginase therapy for leukaemia and other malignant neoplasms. Journal of the American Medical Association, 202, 882.
34. Cammack, K., Marlborough, D., & Miller, D. (1972). Physical properties and subunit structure of L-asparaginase isolated from Erwinia carotovora. Biochemical Journal, 126, 361.
35. Wade, H. E., Ellsworth, R., Herbert, E., Keppie, J., & Sargeant, K. (1968). A new L-asparaginase with antitumor activity? Lancet, 2, 776-777.
36. Roberts, J., Holcenberg, J., & Dolowy, W. (1972). Isolation, crystallization and properties of Achromobacteraceae glutaminase -asparaginase with antitumor activity. Journal of Biological Chemistry, 247, 84.
37. Soru, E., Teodorescu, M., Zaharia, O., Szabados, J., & Rudescu, K. (1972). L-Asparaginase from the BCG strain of Mycobacterium bovis: I. Purification and in vitro immunosuppressive properties. Canadian Journal of Biochemistry, 50, 1149.
38. Dejong, P. J. (1972). L-Asparaginase production by Streptomyces griseus. Applied andEnvironmental Microbiology, 23, 1163.
39. Jones, P., Kristiansen, T., & Einarsson, M. (1973). Purification and properties of L-asparaginase from Acinetobacter calcoaeticus. Biochimica et Biophysica Acta, 327, 146.
40. Lee, B., & Yang, H. (1973). Crystallographic studies on L-Asparaginase from Proteus vulgaris: I. Preliminary crystal data. Journal of Biological Chemistry, 248, 7620.
41. Whelan, H., & Wriston, J. (1974). Purification and properties of L-asparaginase from Serratia marcescens. Biochimica et Biophysica Acta, 365, 212.
42. Mustafa, S. A., & Salama, M. S. (1979). L-Asparaginase producing Streptomyces from soil of Kuwait. Zentralbel Bakterol Naturwiss, 134(4), 325-334.
43. Narayana, K. J. P., Kumar, K. G., & Vijayalakshmi, M. (2007). L-Asparaginase production by Streptomyces albidoflavus. Indian Journal of Microbiology, 48(3), 331-336.
44. Mathews,W., & Brown, H. (1974). Isolation of two L-asparaginases from guinea pig liver. Enzyme, 17, 276.
45. Cooney, D. A., & Handschumacher, R. E. (1970). Evaluation of L-Asparagine metabolism. Annual Review of Pharmacology, 10, 421.
46. Lough, T. J., Reddington, B. D., Grant, M. R., Hill, D. F., Reynolds, P. H. S., & Farnden, K. J. F. (1992). The isolation and characterization of a c DNA clone encoding L-asparaginase from developing seeds of lupin [Lupinus arboreus). Plant Molecular Biology, 19, 391-399.
47. Adamson, R. H., & Fabro, S. (1968). Antitumor activity and other biologic properties of L-asparaginase -review. Cancer Chemotherapy, 52, 617.
48. Siechiechowicz, K., & Ireland, R. (1989). Isolation and properties of an asparaginase from leaves of Pisum sativum. Phytochemistry, 28, 2275.
49. Schwartz, J. H., Reeves, J. Y., & Broome, J. D. (1966). Two L-Asparaginases from E. coli and their action against tumours. Proceedings of the Natlional Academy Sciences USA, 56, 1516-1519 [PubMed: 5339624].
50. Cedar, H., & Schwartz, J. H. (1967). Localization of the two L-asparaginases in anaerobically grown E. coli. Journal of Biological Chemistry, 242, 3753-3755 [PubMed: 4962587].
51. Cedar, H., & Schwartz, J. H. (1968). Production of L-Asparaginase II by E. coli. Journal of Bacteriology, 96, 2043-2048 [PubMed: 4881701].
52. Willis, R. C., &Woolfolk, C. A. (1974). L-Asparagine utilization in E. coli. Journal of Bacteriology, 118, 231-241 [PubMed: 4595199].
53. Casale, T. D., Sollitti, P., & Chesney, R. H. (1983). Cytoplasmic L-asparaginase: Isolation of a defective strain and mapping of ans A. Journal of Bacteriology, 154, 513-515 [PubMed: 6339481].
54. Jennings, M. P., & Beacham, I. R. (1990). Analysis of the E. coli gene encoding L-asparaginase II, ans B, and its regulation by cyclic AMP receptor and FNR proteins. Journal of Bacteriology, 172, 1491-1498 [PubMed: 2407723].
55. Pui, C.-H., Boyett, J. M., Relling, M. V., Harrison, P. L., Rivera, G. K., Behm, F. G., Sandlund, J. T., Riberio, R. C., Rubnitz, J. E., Gajjar, A., & Evans,W. E. (1999). Sex differences in prognosis in children with acute lymphoblastic. Journal of Clinical Oncology, 17, 818.
56. Pui, C. H., Campana, D., & Evans, W. E. (2001). Childhood acute lymphoblastic leukaemia -current status and future perspectives. The Lancet Oncology, 2, 597-607.
57. Jerlstrom, P. G., Bezjak, D. A., Jennings, M. P., & Beacham, I. R. (1989). Structure and expression in E. coli K-12 of the L-Asparaginase I-encoding ans A gene and its flanking regions. Gene, 78, 37-46.
58. Harms, E., Wehner, A., Aung, H. P., & Rohm, K. H. (1991). A catalytic role for threonine-12 of E. coli asparaginase II as established by site-directed mutagenesis. FEBS Letters, 285, 55-58 [PubMed: 1906013].
59. Derst, C., Henseling, J., & Rohm, K. H. (1992). Probing the role of threonine and serine residues of E. coli asparaginase II by site-specific mutagenesis. Protein Engineering, 5, 785-789 [PubMed: 1287659].
60. Wehner, A., Harms, E., Jennings, M. P., Beacham, I. R., Derst, C., Bast, P., & Rohm, K. H. (1992). Sitespecific mutagenesis of E. coli asparaginase II. None of the three histidine residues is required for catalysis. European Journal of Biochemistry, 208, 475-480.
61. Palm, G. J., Lubkowski, J., Derst, C., Schleper, S., Rohm, K. H., & Wlodawer, A. (1996). A covalently bound catalytic intermediate in E. coli asparaginase: Crystal structure of a Thr-89-Val mutant. FEBS Letters, 390, 211-216 [PubMed: 8706862].
62. Swain, A. L., Jaskolski, M., Housset, D., Rao, J. K., & Wlodawer, A. (1993). Crystal structure of E. coli L-Asparaginase, an enzyme used in cancer therapy. Proceedings of the Natlional Academy Sciences USA, 90, 1474-1478 [PubMed: 8434007].
63. Kozak, M., Jasloski, M., & Rohm, K. H. (2000). Preliminary crystallographic studies of 425F mutant of periplasmic Escherichia coli L-asparaginase. Acta Biochimica Polonica, 47(3), 807-814.
64. Aung, H. P., Bocola, M., Schleper, S., & Rohm, K. H. (2000). Dynamics of a mobile loop at the active site of Escherichia coli asparaginase. Biochimica et Biophysica Acta, 1481, 349-359.
65. Jaskolski, M., Kozak, M., Lubkowski, J., Palm, G., & Wlodawer, A. (2001). Structures of two highly homologous bacterial L-asparaginases: A case of enantiomorphic space groups. Acta Crystallographica. Section D, Biological Crystallography, 57, 369-377.
66. Kozak, M., & Jurga, S. (2002). A comparison between the crystal and solution structures of E. coli asparaginase II. Acta Biochimica Polonica, 49, 509-513 [PubMed: 12362993].
67. Sanches, M., Barbosa, J. A., de Oliveira, R. T., Abrahao, N. J., & Polikarpov, I. (2003). Structural comparison of E. coli L-asparaginase in two monoclinic space groups. Acta Crystallographica. Section D, Biological Crystallography, 59, 416-422 [PubMed: 12595697].
68. Howard, J. B., & Carpenter, F. H. (1972). L-Asparaginase from Erwinia carotovora. Substrate specificity and enzymatic properties. Journal of Biological Chemistry, 247, 1020-1030.
69. Miller, M., Rao, J. K., Wlodawer, A., & Gribskov, M. R. (1993). A left-handed crossover involved in amidohydrolase catalysis. Crystal structure of Erwinia chrysanthemi l-asparaginase with bound laspartate. FEBS Letters, 328, 275-279.
70. Aghaiypour, K., Wlodawer, A., & Lubkowski, J. (2001). Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase. Biochemistry, 40, 5655-5664.
71. Lubkowski, J., Dauter, M., Aghaiypour, K., Wlodawer, A., & Dauter, Z. (2003). Atomic resolution structure of Erwinia chrysanthemi L-asparaginase. Acta Crystallographica. Section D, Biological Crystallography, 59, 84-92.
72. Lubkowski, J., Palm, G. J., Gilliland, G. L., Derst, C., Röhm, K. H., & Wlodawer, A. (1996). Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase. European Journal of Biochemistry, 241, 201-207.
73. Lubkowski, J., Wlodawer, A., Ammon, H. L., Copeland, T. D., & Swain, A. L. (1994). Structural characterization of Pseudomonas 7A glutaminase- asparaginase. Biochemistry, 33, 10257-10265.
74. Lubkowski, J., Wlodawer, A., Housset, D., Weber, I. T., Ammon, H. L., Murphy, K. C., & Swain, A. L. (1994). Refined crystal structure of Acinetobacter glutaminasificans glutaminase-asparaginase. Acta Crystallographica. Section D, Biological Crystallography, 50, 826-832.
75. Ortlund, E., LaCount, M. W., Lewinski, K., & Lebioda, L. (2000). Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and L-Asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu. Biochemistry, 39, 1199-1204.
76. Broome, J. D. (1968). Studies on the mechanism of tumor inhibition by L-asparaginase: Effects of the enzyme on L-Asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: Differences in L-Asparagine formation and utilization in asparaginase sensitive and -resistant lymphoma cells. The Journal of Experimental Medicine, 127, 1055-1072.
77. Avramis, V. I., & Panosyan, E. H. (2005). Pharmacokinetic/ pharmacodynamic basis for some drugrelated side effects. European Journal of Clinical Investigation, 44, 367-393. 1055-1072.
78. Badr El Din, S. M., & Foda, M. S. (1976). Kinetics and properties of L-glutaminase EC-3.5.1.2 and Lasparaginase EC-3.5.1.1 activities of Pseudomonas ovalis. Zentralblatt fuer Bakteriologie Parasitenkunde Infektionskrankheiten und Hygiene Zweite Naturwissenschafliche Abteilung Allgemeine Landwirtschaftliche und Technische. Mikrobiologie, 131(6), 489-496.
79. Stern, M. L., Phillips, A. W., & Gottlieb, A. J. (1976). Physical properties of L-asparaginase from Serratia marcescens. Journal of Bacteriology, 125(2), 719-727.
80. Jones, G. E. (1977). Genetic and physiological relationships between L-asparaginase I and L-asparaginase II Saccharomyces cerevisiae. Journal of Bacteriology, 130(1), 128-130.
81. Paul, J. H., & Cooksey, K. E. (1981). Regulation of L-Asparaginase E.C.-3.5.1.1 in a Chlamydomonas species in response to ambient concentrations of combined nitrogen. Journal of Bacteriology, 147(1), 9-12.
82. Borkotaky, B., & Bezbaruah, R. L. (2002). Production and properties of asparaginase from a new Erwinia sp. Folia Microbiologica, 47(5), 473-476.
83. Minim, L. A., & Alegre, M. (1992). Production of enzyme L-Asparaginase from Erwinia aroideae. Arquivos de Biologia e Tecnologia (Curitiba), 35(2), 277-283.
84. Ramaiah, N., & Chandramohan, D. (1992). Production of L-asparaginase from marine luminous bacteria. Indian Journal of Marine Sciences, 21(3), 212-214.
85. Mishra, A. (2006). Production of L-asparaginase, an anticancer agent, from Aspergillus niger using agricultural waste in solid state fermentation. Applied Biochemistry and Biotechnology, 135(1), 33-42.
86. Netrval, J. (1977). Stimulation of L-asparaginase production in Escherichia coli by organic and amino acids. Folia Microbiologica, 22(2), 106-116.
87. Goward, C. R., Stevens, G. B., Collins, I. J., Wilkinson, I. R., & Scawen, M. D. (1989). Use of macrosorb keiselguhr composite and CM-sepharose fast flow for the large-scale purification of Lasparaginase from Erwinia chrysanthemi. Enzyme and Microbial Technology, 11(12), 810-814.
88. Kumar, S., Venkata Dasu, V., & Pakshirajan, K. (2010). Localization and production of novel Lasparaginase from Pectobacterium carotovorum MTCC 1428. Process Biochemistry, 45, 223-229.
89. Pui, C. H., & Evans, W. E. (2006). Treatment of acute lymphoblastic leukaemia. The New England Journal of Medicine, 354(2), 166-178.
90. Avramis, V. I., Sencer, S., Periclou, A. P., Harland, S., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Hilden, J. M., Lange, B., Majilessipour, F. A. T., Pracad, M., Needle, M., Nehlia, J., Reaman, G., & Holcenberg, J. S. (2002). A randomized comparison of native E. coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standardrisk acute lymphoblastic leukaemia: A Children's Cancer Group study. Blood, 99, 1986-1994.
91. Douer, D., Yampolsky, H., Cohen, L. J., Watkins, K., Levine, A. M., Periclou, A. P., & Avramis, V. I. (2007). Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukaemia. Blood, 109, 2744-2750.
92. Wetzler, M., Sanford, B. L., Kurtzberg, J., DeOliveira, D., Frankel, S. R., Powell, B. L., Kolitz, J. E., Bloomfield, C. D., & Larson, R. A. (2007). Effective L-Asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukaemia: Cancer and Leukaemia Group B Study 9511. Blood, 109, 4164-4167.
93. Loh, M. L., Goldwasser, M. A., Silverman, L. B., Poon, W. M., Vattikuti, S., Cardoso, A., Neuberq, D. S., Shannon, K. M., & Gilliland, D. G. (2006). Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood, 107, 4508-4513.
94. Harms, D. O., Gobel, U., Spaar, H. J., Graubner, U. B., Jorch, N., Gutjahr, P., & Janka-Schaub, G. E. (2003). Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: Results of the randomized trial COALL-92. Blood, 102, 2736-2740.
95. Lange, B. J., Bostrom, B. C., Cherlow, J. M., Sensel, M. G., La, M. K., Rackoff, W., Heerema, N. A., Wimmer, R. S., Triqq, M. E., & Sther, H. N. (2002). Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukaemia: A report from the Children's Cancer Group. Blood, 99, 825-833.
96. Hoelzer, D., & Gokbuget, N. (2000). New approaches to lymphoblastic leukaemia in adults: Where do we go? Seminars in Oncology, 27, 540-559.
97. Kantarjian, H., Thomas, D., O'Brien, S., Cortes, J., Giles, F., Jeha, S., Bueso-Ramos, C. E., Pierce, S., Shan, J., Koller, C., Beran, M., Keatinq, M., & Freireich, E. J. (2004). Long-term follow-up results of hyper fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone [Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukaemia. Cancer, 101, 2788-2801.
98. Linker, C., Damon, L., Ries, C., & Navarro,W. (2002). Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukaemia. Journal of Clinical Oncology, 20, 2464-2471.
99. Stock, W., La, M., Sanford, B., Bloomfield, C. D., Vardiman, J. W., Gavnon, P., Larson, R. A., & Nachman, J. (2008). What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group b studies. Blood, 112, 1646-1654.
100. Vora, A., Mitchell, C. D., Lennard, L., Eden, T. O. B., Kinsey, S. E., Lilleyman, J., & Richards, S. M. (2006). Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: A randomised trial. Lancet, 368, 1339-1348.
101. Nesbit, M., Chard, R., Evans, A., Karon, M., & Hammond, G. D. (1979). Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. The American Journal of Pediatric Hematology/Oncology, 1, 9-13.
102. Clavell, L. A., Gelber, R. D., Cohen, H. J., Hitchcock-Bryan, S., Cassady, J. R., Tarbell, N. J., Blattner, S. R., Tantravahi, R., Leavitt, P., & Sallan, S. E. (1980). Four-agent induction and intensive Lasparaginase therapy for treatment of childhood acute lymphoblastic leukaemia. New England Journal of Medicine, 315, 657-663.
103. Desai, S., Barr, R., Andrew, M., deVeber, L., & Pai, M. (1989). Management of Ontario children with acute lymphoblastic leukaemia by the Dana-Farber Cancer Institute Protocols. Canadian Medical Association Journal, 141, 693.
104. Nachman, J., Sather, H. N., Gaynon, P. S., Lukens, J. N., Wolff, L., & Trigg, M. E. (1997). Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy of children and adolescents with acute lymphoblastic leukaemia and unfavourable presenting features: A report from children's Cancer Group. Journal of Clinical Oncology, 15, 222-230.
105. Grahm, M. L., Asselin, B. L., Herndon, J. E., Casey, J. R., Chaffee, S., Cioccci, G. H., Daeschner, C.W., Davis, A. R., Gold, S., Halperin, E. C., Laughlin, M. J., Martin, P. L., Olson, J. F., & Kurtzberg, J. (1998). Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplantation, 21, 879-885.
106. Muller, H. J., & Boos, J. (1998). Use of L-asparaginase in childhood ALL. Critical Reviews in Oncology/ Hematology, 282, 97-113.
107. Amylon, M. D., Shuster, J., & Ja, P. (1999). Intensive high-dose asparaginase consolidation improves survival for paediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Paediatric Oncology Group study. Leukemia, 13, 335-342.
108. Sallan, S. E., Hitchcock-Bryan, S., & Gelber, R. (1983). Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukaemia. Cancer Research, 43, 5601-5607.
109. Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P., & Buchanan, G. R. (2000). Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukaemia: A Pediatric Oncology Group Study. Blood, 96, 1709-1715.
110. Pession, A., Valsecchi, M. G., Masera, G., Kamps,W. A., Magyarosy, E., Rizzari, C., VanWering, E. R., Lo Nigro, L., Vander Does, A., Locatelli, F., Basso, G., & Arico, M. (2005). Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukaemia. Journal of Clinical Oncology, 23, 7161-7167.
111. Moghrabi, A., Levy, D. E., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Samson, Y., Schorin, M., Dalton, V. K., Lipshultz, S. E., Neuberg, D. S., Gelber, D. R., Cohen, H. J., Sallan, S. E., & Silverman, L. B. (2007). Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukaemia. Blood, 109, 896-904.
112. Asselin, B. L., Kreissman, S., Coppola, D. J., Bernal, S. D., Leavitt, P. R., Gelber, R. D., Sallan, S. E., & Cohen, H. J. (1999). Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukaemia. Journal of Pediatric Hematology/Oncology, 21, 6-12.
113. Wikman, L. E., Krasotkina, J., Kuchumova, A., Sokolov, N. N., & Papageorgiou, A. C. (2005). Crystallization and preliminary crystallographic analysis of L-Asparaginase from Erwinia carotovora. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications, 61, 407-409.
114. Aghaiypour, K., Wlodawer, A., & Lubkowski, J. (2001). Do bacterial L-asparaginases utilize a catalytic triad Thr-Tyr-Glu? Biochimica et Biophysica Acta, 1550, 117-128.
115. Aghaiypour, K., Wlodawer, A., & Lubkowski, J. (2001). Do bacterial L-asparaginases utilize a catalytic triad Thr-Tyr-Glu? Biochemica et Biophysica Acta, 1550, 117-128.
116. Jackson, R. D., Handschumacher, R. E. (1970). E. coli L-asparaginase: Catalytic activity and subunit nature. Biochem.
117. Harrison, P. L., Wang, B., Pui, C.-H., Relling, M. V. Cerebrospiistry, 9:3585-3590
118. Maita, T., & Matsuda, G. (1980). The primary structure of L-asparaginase from Escherichia coli. Hoppe-Seyler's Z Physiol Chem, 361, 105-117.
119. Kozak, M., Borek, D., Janowski, R., & Jaskolski, M. (2002). Crystallization and preliminary crystallographic studies of negative crystal forms of Escherichia coli L-asparaginase II [Asp90Glu mutant). Acta Crystallographica Section D Biological Crystallography, 58, 130-132.
120. Kirchbaum, J., Wriston, J. C., & Ratych, O. T. (1969). Subunit structure of asparaginase from Escherichia coli B. Biochimica et Biophysica Acta Protein Structure, 194, 161-169.
121. Shifrin, S., Luborsky, S. W., & Grochowski, B. J. (1971). L-Asparaginase from Escherichia coli B. Physicochemical studies of the dissociation process. Journal of Biological Chemistry, 246, 7708-7714.
122. Eden, O. B., Shaw, M. P., Lilleyman, J. S., & Richards, S. (1990). Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Medical and Pediatric Oncology, 18, 497-502.
123. Kabsch, W. (1993). Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. Journal of Applied Crystallography, 26, 795-800.
124. Carlsson, H., Stockelberg, D., Tengborn, L., Braide, I., Carneskog, J., & Kutti, J. (1995). Effects of Erwinia-asparaginase on the coagulation system. European Journal of Haematology, 55, 289-293.
125. Goldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. K., Gelber, R. D., Lehmann, L., Cohen, H. J., Sallan, S. E., & Asselin, B. L. (2003). Childhood T-cell acute lymphoblastic leukaemia: The Dana-Farber Cancer Institute acute lymphoblastic leukaemia consortium experience. Journal of Clinical Oncology, 21, 3616-3622.
126. Avramis, V. I., & Tiwari, P. N. (2006). Asparaginase [native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukaemia. International Journal of Nanomedicine, 1, 241-254.
127. Vieira Pinheiro, J. P., Wenner, K., Escherich, G., Lanvers-Kaminsky, C., Wurthwein, G., Janka-Schaub, G., & Boos, J. (2006). Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m2 PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatric Blood & Cancer, 46, 18-25.
128. Narta, U. K., Kanwar, S. S., & Azmi, W. (2007). Pharmacological and clinical evaluation of Lasparaginase in the treatment of leukemia. Critical Reviews in Oncology/Hematology, 61, 208-221.
129. Janin, J., Rodier, F., Chakrabarti, P., & Bahadur, R. (2007). Macromolecular recognition in the Protein Data Bank. Acta Crystallographica. Section D, Biological Crystallography, 63, 1-8.
130. Park, Y. K., Abuchowski, A., Davis, S., & Davis, F. (1981). Pharmacology of E. coli L-asparaginase polyethylene glycols adduct. Anticancer Research, 1, 373-376.
131. Kurtzberg, J., Friedman, H., Asselin, B., et al. (1990). The use of polyethylene glycol-conjugated Lasparaginase [PEG-Asp) in paediatric patients with prior hypersensitivity to native L-asparaginase. American Society of Clinical Oncology, 9, 219.
132. Ettinger, L., Asselin, B., Poplack, D., Kurtzberg, J. (1993). Toxicity profile of PEG-L-asparaginase in native L-asparaginase-hypersensitive and non hypersensitive patients with acute lymphoblastic leukaemia (ALL). Presented at international Society of Paediatric Oncology [SIOP) 25th meeting.
133. Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002). Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews, 54, 459-476.
134. Schellekens, H. (2002). Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clinical Therapeutics, 24, 1720-1740.
135. Mitchell, L., Hoogendoorn, H., Giles, A. R., Vegh, P., & Andrew, M. (1994). Increased endogenous thrombin generation in children with acute lymphoblastic leukaemia: Risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood, 83, 386.
136. Gugliotta, L., Mazzucconi, M. G., Leone, G., Mattioli-Belmonte, M., Defazio, D., Annino, L., Tura, S., Mandelli, F., & the GIMEMA Group. (1992). Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: A retrospective study. European Journal of Haematology, 49, 63.
137. Andersen, E., & Videbaek, A. (1980). Procarbazine-induced skin reactions in Hodgkin's disease and other malignant lymphomas. Scandinavian Journal of Haematology, 24, 149-151.
138. Priest, J. R., Ramsay, N. K. C., Latchaw, R. E., Lockman, L. A., Hasegawa, D. K., Coates, T. D., Coccia, P. F., Edson, J. R., Nesbit, M. E., & Krivit,W. (1980). Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer, 46, 1548-1554.
139. Homans, A. C., Ryback, M. E., Baglini, R. L., Tiarks, C., Steiner, M. E., & Forman, E. N. (1987). Effect of L-Asparginase administration on coagulation and platelet function in children with leukemia. Journal of Clinical Oncology, 5, 811-817.
140. Barbui, T., Rodeghiero, F., Meli, S., & Dini, E. (1983). Fatal pulmonary embolism and antithrombin 111 deficiency in adult lymphoblastic leukemia during L-asparaginase therapy. Acta Haematologica, 69, 188.
141. Vigano-D'Angelo, S., Gugliotta, L., Mattioli, B., Cascione, M. L., Pattarina, E., & D'Angelo, A. (1990). L-Asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation. Thrombosis Research, 59, 985.
142. Trivedi, C. D., & Pitchumoni, C. S. (2005). Drug induced pancreatitis: An update. Journal of Clinical Gastroenterology, 39(8), 709-716.
143. Aoki, C. A., Bowlus, C. L., & Rossaro, L. (2005). An adult case of acute lymphoblastic leukemia presenting as hepatic dysfunction. Digestive and Liver Disease, 37(3), 206-210.
144. Brodtman, D. H., Rosenthal, D. W., Redner, A., Lanzkowsky, P., & Bonagura, V. R. (2005). Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. Journal of Pediatrics, 146(5), 654-661.
145. Sahoo, S., & Hart, J. (2003). Histopathological features of L-asparaginase induced liver disease. Seminars in Liver Disease, 23(3), 295-299.
146. Imamura, T., Morimoto, A., Kato, R., Izumi, M., Murakami, A., Matuo, S., Kivosawa, N., Kano, G., Yoshioka, H., Sugimoto, T., & Imashuku, S. (2005). Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase containing chemotherapy. Leukemia & Lymphoma, 46(5), 729-735.
147. Haddy, T. B., Mosher, R. B., Nunez, S. B., & Reaman, G. H. (2006). Growth hormone deficiency after chemotherapy for acute lymphoblastic leukaemia in children who have not received cranial radiation. Pediatric Blood & Cancer, 46(2), 258-261.
148. Hernández-Espinosa, D., Minano, A., Martinez, C., Pérez-Ceballos, E., Heras, I., Fuster, J. L., Vicente, F. V., & Corral, J. (2006). L-Asparaginase-induced antithrombin type I deficiency. American Journal of Pathology, 169, 142-153.
149. Mitchell, L., Hoogendoorn, H., & Giles, A. R. (1994). Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in L-asparaginase induced antithrombin III deficiency. Blood, 83(2), 386-391.
150. Omoti, A. E., & Omoti, C. E. (2006). Ocular toxicity of systemic anticancer chemotherapy. Pharmacy Practice, 4(2), 55-59.
151. Saviola, A., Luppi, M., Potenza, L., Morselli, M., Bresciani, P., Ferrari, A., Riva, G., & Torelli, G. (2004). Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. European Journal of Haematology, 72(1), 71-72.
152. Ortega, J. A., Nesbit, M. E., & Donaldson, M. H. (1977). L-Asparaginase, vincristine and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Research, 37, 535-540.
153. Sutow, W. W., Garcia, F., & Starling, K. A. (1971). L-Asparaginase therapy in children with advanced leukemia. Cancer, 28, 819-824.
154. Nakamura, N., Marikina, Y., & Tanaka, M. (1971). L-Asparaginase from E. coli: Part II. Substrate specificity studies. Agricultural and Biological Chemistry, 35(5), 743-751.
155. Oettgen, H. F., Stephenson, P. A., Schwartz, M. K., Leeper, R. D., Tallal, L., Tan, C. C., Clarkson, B. D., Golbey, R. B., Krakoff, I. H., Karnofsky, D. A., Murphy, L., Burchenal, J. H., et al. (1970). Toxicity of E. coli L-asparaginase in man. Cancer, 25, 253-278.
156. Zollner, N., & Heimstadt, P. (1971). Effects of a single administration of L-asparaginase on serum lipids. Nutrition and Metabolism, 13, 344.
157. Favrot, M. C., Dallamonica, C., & Soullet, G. (1983). Study of blood lipids in 30 children with a malignant hematological disease or carcinoma. Biomedicine & Pharmacotherapy, 37, 55.
158. Steinherz, P. G. (1994). Transient, severe hyperlipidemia in patients with acute lymphoblastic leukaemia treated with prednisone and asparaginase. Cancer, 74, 3234.
159. Meyer, B., Hagen, W., Scheithauer, W., Ohler, L., & Kornek, G. V. (2003). L-Asparaginase-associated hyperlipidemia with hyperviscosity syndrome in a patient with T-cell lymphoblastic. Annals of Oncology, 14(4), 658-659.
160. Parsons, S. K., Skapek, S. X., Neufeld, E. J., Kuhlman, C., Young, M. L., Donnelly, M., Brunzell, J. D., Otvos, J. D., Sallan, S. E., & Rifai, N. (1997). Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood, 6, 1886-1895.
161. Land, V. J., Sutow, W. W., Fernbach, D. J., Lane, D. M., & Williams, T. E. (1972). Toxicity of Lasparaginase in children with advanced leukemia. Cancer, 30, 339-347.
162. Oettgen, H. F., Stephenson, P. A., Schwartz, M. K., Leeper, R. D., Tallai, L., Tan, C. C., Clarkson, B. D., Golbey, R. B., Krakoff, I. H., Karnofsky, D. A., Murphy, M. L., & Borchenal, J. H. (1970). Toxicity of E. coli L-asparaginase in man. Cancer, 25, 253.
163. Ohnuma, T., Holland, J. F., Nagal, G., & St. Arneault, G. (1969). Effects of L-asparaginase in acute myelocytic leukemia. Journal of the American Medical Association, 210, 1919-1921.
164. González, D., Salazar Saez, R., Moreno Rodilla, E., Laffond Yges, Y. E., & Lorente Toledano, F. (2000). Hypersensitivity reactions to chemotherapy drugs. Clinical Reviews in Allergy & Immunology, 15, 161-181.
165. Korholz, D., Urbanek, R., Nurnberger, W., Jobke, A., Gobel, U., & Wahn, V. (1987). Formation of specific IgG antibodies in L-asparaginase treatment. Distribution of IgG subclasses. Monatsschrift Kinderheilkunde, 135, 325-328.
166. Rossi, F., Incorvaia, C., & Mauro, M. (2004). Hypersenstivity reactions to chemotherapeutic antineoplastic agents. Recenti Progressi in Medicina, 95(10), 476-481.
167. Krasotkina, J., Borisova, A. A., Gervaziew, Y. V., & Sokolov, N. N. (2004). One-Step Purification and kinetic properties of the recombinant L-Asparaginase from Erwinia carotovora. Biotechnology and Applied Biochemistry, 39, 215-221.
168. Kravchenko, O. V., Kislitsin, Yu. A., Popov, A. N., Nikonov, S. V., & Kuranova, I. P. (2008). Threedimensional structures of L-asparaginase from Erwinia carotovora complexed with aspartate and glutamate. Acta Crystallographica, D64, 248-256.
169. Ollenschlager, G., Roth, E., Linkesch, W., Jansen, S., Simmel, A., & Modder, B. (1988). Asparaginaseinduced derangements of glutamine metabolism: The pathogenetic basis for some drug-related sideeffects. European Journal of Clinical Investigation, 18, 512-516.
170. Derst, C., Henseling, J., & Röhm, K. H. (2000). Engineering the substrate specificity of Escherichia coli asparaginase: II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Science, 9, 2009-2017.
171. Kumar, S., Pakshirajan, K., & Venkata Dasu, V. (2009). Development of medium for enhanced production of glutaminase-free L-asparaginase from Pectobacterium carotovorum MTCC 1428. Applied Microbiology and Biotechnology, 84, 477-486.
172. Kumar, S., Pakshirajan, K., & Venkata Dasu, V. (2010). Assessment of physical process conditions for enhanced production of novel glutaminase-free L-Asparaginase from Pectobacterium carotovorum MTCC 1428. Applied Biochemistry and Biotechnology, 163, 327-337.
173. Manna, S., Sinha, A., Sadhukhan, R., & Chakrabarty, S. L. (1995). Purification, characterization and antitumor activity of L-asparaginase isolated from Pseudomonas stutzeri MB-405. Current Microbiology, 30, 291-298.
174. Ramya, L. N., Doble, M., Rekha, V. P. B., & Pulicherla, K. K. (2011). In silico engineering of LAsparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukaemia. Journal of Pediatric Hematology/Oncology, 33(8), 617-621.